Viroptic®
trifluridine 1.0% · ophthalmic solution
Antiviral
Approved uses
Primary herpetic keratoconjunctivitis and recurrent epithelial keratitis, HSV types 1 and 2
One drop onto the cornea of the affected eye every 2 hours while awake, to a maximum of nine drops daily, until the ulcer re-epithelializes; then one drop every 4 hours while awake for a further 7 days, for a minimum of five drops daily
The 21-day ceiling matters: beyond it the corneal toxicity outweighs the antiviral effect
Contraindications
Trifluridine Ophthalmic Solution is contraindicated for patients who develop hypersensitivity reactions or chemical intolerance to trifluridine.
Trifluridine ophthalmic solution 1%, 7.5 mL fill in a plastic bottle
Trifluridine interferes with DNA synthesis in cultured mammalian cells. However, its antiviral mechanism of action is not completely known.
Warnings & Precautions
- Recommended dosage and frequency: The recommended dosage and frequency of administration should not be exceeded.
- Clinical diagnosis of herpetic keratitis: Prescribe only for patients who have a clinical diagnosis of herpetic keratitis.
- Local irritation: Trifluridine may cause mild local irritation of the conjunctiva and cornea when instilled, but these effects are usually transient.
- Viral resistance: Documented in vitro viral resistance has not been reported after multiple exposure to trifluridine, but the possibility of the development of viral resistance exists.
- Ocular toxicity: If there are no signs of improvement after 7 days or complete re-epithelialization has not occurred after 14 days, consider other therapy; avoid continuous administration for periods exceeding 21 days because of potential ocular toxicity.
Common Side Effects
The most frequent adverse reactions reported during controlled clinical trials were mild, transient burning or stinging upon instillation and palpebral edema. Other adverse reactions in decreasing order of reported frequency were superficial punctate keratopathy, epithelial keratopathy, hypersensitivity reaction, stromal edema, irritation, keratitis sicca, hyperemia, and increased intraocular pressure.
Pregnancy: Trifluridine was not teratogenic at subcutaneous doses up to 5 mg/kg/day (23 times the estimated human exposure) in rats and rabbits, but fetal toxicity (delayed ossification of portions of the skeleton) occurred at 2.5 and 5 mg/kg/day in rats and at 2.5 mg/kg/day in rabbits, and both 2.5 and 5 mg/kg/day produced fetal death and resorption in rabbits; there are no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus.
Lactation: Excretion in human milk after ophthalmic instillation is unlikely because of the relatively small dosage (5 mg/day), dilution in body fluids and extremely short half-life (approximately 12 minutes); the drug should not be prescribed for nursing mothers unless the potential benefits outweigh the potential risks.
≥6 years